Maximizing the Potential of Liver Fibrosis Assay
Drug discovery is a complex and challenging process that requires a significant investment of time, resources, and expertise. One [...]
A Closer Look at Visikol’s Liver Fibrosis Assay
Traditionally, animal models have been used to study the effects of drugs in living organisms. However, there are differences [...]
Human Liver Diseases and Hepatocyte In Vitro Cell Culture Model
The human liver is a remarkable organ with vital functions that impact metabolism, detoxification, and protein synthesis. Understanding liver [...]
How Visikol’s Liver Fibrosis Assay is Accelerating the Development of Therapeutics
Drug discovery is a complex process that involves identifying and developing new drugs to treat a wide range of [...]
Human Hepatocyte Spheroid Model to Study NASH
Non-alcoholic steatohepatitis (NASH) is a progressive disease which results in advancement of liver fibrosis, cirrhosis, and hepatocellular carcinoma, for which [...]
LC-MS/MS Quantification of the Methylation Status of Clinical Samples of NASH Liver Tissues
Nonalcoholic fatty liver disease (NAFLD) is a common hepatic disorder in individuals who drink little or no alcohol. A [...]
An In-Depth Look at PCLS Models
Non-alcoholic fatty liver disease (NAFLD) is the most chronic form of liver disease, which affects about quarter of the [...]
The Advantage of Using Visikol Assays to Study NASH
Non-alcoholic fatty liver disease (NAFLD) is a common condition and estimates indicate almost 1 in 4 adults in the [...]
Visikol to present at SELECTBIO’s December 2021 Conference
Visikol's Director of Drug Discovery, Peter Worthington Ph.D., to Present at SELECTBIO's 3D-Cell Culture, Organoids, and Organs-on-Chips Conference [...]
Assessing Promising NASH Compounds
Nonalcoholic steatohepatitis (NASH) is a disease of the liver characterized by inflammation, cell injury and fibrosis. Progression of this [...]